Find Insulin aspart manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

38 RELATED EXCIPIENT COMPANIES

72EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Dtxsid10151274
Molecular Formula
C256H387N65O79S6
Molecular Weight
5832  g/mol
InChI Key
VOMXSOIBEJBQNF-UTTRGDHVSA-N

Insulin aspart
1 2D Structure

Insulin aspart

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
2.1.2 InChI
InChI=1S/C157H232N40O44S2.C99H155N25O35S4/c1-77(2)54-102(180-130(214)84(15)172-135(219)101(48-51-123(210)211)179-152(236)126(82(11)12)194-149(233)105(57-80(7)8)183-145(229)111(64-93-68-165-76-171-93)188-151(235)114(72-198)175-121(207)71-169-133(217)115(73-242)191-140(224)103(55-78(3)4)181-144(228)110(63-92-67-164-75-170-92)187-137(221)100(46-49-117(160)203)178-146(230)112(65-118(161)204)189-153(237)125(81(9)10)193-131(215)96(159)58-87-30-21-18-22-31-87)139(223)184-108(61-90-38-42-94(201)43-39-90)142(226)182-104(56-79(5)6)148(232)195-127(83(13)14)154(238)192-116(74-243)134(218)168-69-119(205)173-99(47-50-122(208)209)136(220)176-97(37-29-53-166-157(162)163)132(216)167-70-120(206)174-106(59-88-32-23-19-24-33-88)141(225)185-107(60-89-34-25-20-26-35-89)143(227)186-109(62-91-40-44-95(202)45-41-91)150(234)196-128(85(16)199)155(239)190-113(66-124(212)213)147(231)177-98(36-27-28-52-158)138(222)197-129(86(17)200)156(240)241;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,30-35,38-45,67-68,75-86,96-116,125-129,198-202,242-243H,27-29,36-37,46-66,69-74,158-159H2,1-17H3,(H2,160,203)(H2,161,204)(H,164,170)(H,165,171)(H,167,216)(H,168,218)(H,169,217)(H,172,219)(H,173,205)(H,174,206)(H,175,207)(H,176,220)(H,177,231)(H,178,230)(H,179,236)(H,180,214)(H,181,228)(H,182,226)(H,183,229)(H,184,223)(H,185,225)(H,186,227)(H,187,221)(H,188,235)(H,189,237)(H,190,239)(H,191,224)(H,192,238)(H,193,215)(H,194,233)(H,195,232)(H,196,234)(H,197,222)(H,208,209)(H,210,211)(H,212,213)(H,240,241)(H4,162,163,166);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t84-,85+,86+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,125-,126-,127-,128-,129-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
2.1.3 InChI Key
VOMXSOIBEJBQNF-UTTRGDHVSA-N
2.1.4 Canonical SMILES
CCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CS)C(=O)NC(CS)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CS)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)CN.CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CS)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC5=CN=CN5)NC(=O)C(CO)NC(=O)CNC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(CC6=CN=CN6)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC7=CC=CC=C7)N
2.1.5 Isomeric SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CC=CC=C7)N)O
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. Dtxsid10151274

2.3 Create Date
2007-07-03
3 Chemical and Physical Properties
Molecular Weight 5832 g/mol
Molecular Formula C256H387N65O79S6
Hydrogen Bond Donor Count86
Hydrogen Bond Acceptor Count91
Rotatable Bond Count188
Exact Mass5829.6654893 g/mol
Monoisotopic Mass5827.6587796 g/mol
Topological Polar Surface Area2350 Ų
Heavy Atom Count406
Formal Charge0
Complexity13000
Isotope Atom Count0
Defined Atom Stereocenter Count52
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameNovolog
PubMed HealthInsulin Aspart Protamine/Insulin Aspart (Injection)
Drug ClassesAntidiabetic
Drug LabelNovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b...
Active IngredientInsulin aspart recombinant
Dosage FormInjectable
RouteSubcutaneous
Strength1000 units/10ml (100 units/ml)
Market StatusPrescription
CompanyNovo Nordisk

2 of 2  
Drug NameNovolog
PubMed HealthInsulin Aspart Protamine/Insulin Aspart (Injection)
Drug ClassesAntidiabetic
Drug LabelNovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a human insulin analog suspension containing 70% insulin aspart protamine crystals and 30% soluble insulin aspart. NovoLog Mix 70/30 is a b...
Active IngredientInsulin aspart recombinant
Dosage FormInjectable
RouteSubcutaneous
Strength1000 units/10ml (100 units/ml)
Market StatusPrescription
CompanyNovo Nordisk

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1661193000,"product":"ANIA211201 RECOMBINANT INSULIN ASPART","address":"PLOT NO18 INTERNATIONAL BIOTECH,PA RK HINJAWADI PHASE II","city":"PUNE,MAHARASHTRA","supplier":"WUXI LIANYIN IMPORT-EXPORT TRADING CO., LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"BIOPHARM","customerCountry":"INDIA","quantity":"0.20","actualQuantity":"200.16","unit":"GMS","unitRateFc":"79.9","totalValueFC":"16187.6","currency":"USD","unitRateINR":"6434.9","date":"23-Aug-2022","totalValueINR":"1288000","totalValueInUsd":"16187.6","indian_port":"BOMBAY AIR","hs_no":"29371200","bill_no":"2129814","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO18 INTERNATIONAL BIOTECH,PA RK HINJAWADI PHASE II"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695234600,"product":"INSULIN ASPART (RDNA ORIGIN)BULK","address":"BIOCON PARK, PLOT NO.2,3,4 AND 5,,","city":"BANGALORE,KARNATAKA","supplier":"BIOCON","supplierCountry":"MALAYSIA","foreign_port":"N\/A","customer":"BIOCON","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"8","unit":"GMS","unitRateFc":"123","totalValueFC":"995.2","currency":"USD","unitRateINR":"10325.9","date":"21-Sep-2023","totalValueINR":"82607","totalValueInUsd":"995.2","indian_port":"Biocon-SEZ","hs_no":"29371200","bill_no":"1013046","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MALAYSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"NO.1,JALAN BIOTEKNOLOGI 1 KAWASAN PERINDUSTRIAN SILC JOHOR,79200, MALAYSIA MY","customerAddress":"BIOCON PARK, PLOT NO.2,3,4 AND 5,,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698172200,"product":"INSULIN ASPART PROCESS INTERMEDIATE","address":"BIOCON PARK, PLOT NO.2,3,4 AND 5,,","city":"BANGALORE,KARNATAKA","supplier":"BIOCON","supplierCountry":"MALAYSIA","foreign_port":"N\/A","customer":"BIOCON","customerCountry":"INDIA","quantity":"15.47","actualQuantity":"15470","unit":"GMS","unitRateFc":"123","totalValueFC":"1925002.5","currency":"USD","unitRateINR":"10356.6","date":"25-Oct-2023","totalValueINR":"160216602","totalValueInUsd":"1925002.5","indian_port":"Biocon-SEZ","hs_no":"29371200","bill_no":"1014561","productDescription":"Intermediate","marketType":"LESS REGULATED MARKET","country":"MALAYSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"NO.1,JALAN BIOTEKNOLOGI 1 KAWASAN PERINDUSTRIAN SILC JOHOR,79200, MALAYSIA MY","customerAddress":"BIOCON PARK, PLOT NO.2,3,4 AND 5,,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715538600,"product":"RECOMBINANT INSULIN ASPART ( SAMPLE FOR TESTING PURPOSE )","address":"301\/A, SHREYA HOUSE, PEREIRA HILL","city":"MUMBAI, MAHARASHTRA.","supplier":"DONGBAO IMPORT AND EXPORT TRADING (","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"BIOPHARM","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"55500","totalValueFC":"56163.1","currency":"USD","unitRateINR":"4681425","date":"13-May-2024","totalValueINR":"4681425","totalValueInUsd":"56163.1","indian_port":"Bombay Air","hs_no":"29371200","bill_no":"3453836","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"HAINAN) CO., LTDROOMS 30-246 ,5 THFLOOR , BUILDING A , ENTREPRENEURSHIPINCUBATION CENTER ,226 NANHAI AVE CHINA","customerAddress":"301\/A, SHREYA HOUSE, PEREIRA HILL"}]
23-Aug-2022
13-May-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Parenteral

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Direct Compression

read-more
read-more

Co-Processed Excipients

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Coating Systems & Additives

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

API Stability Enhancers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Controlled & Modified Release

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : NovoMix

Biphasic Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : NovoMix

Denmark
arrow
CPHI Middle east
Not Confirmed

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,567

2019 Revenue in Millions : 1,559

Growth (%) : 1

blank

02

Brand Name : Fiasp

Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : Fiasp

Denmark
arrow
CPHI Middle east
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 225

2019 Revenue in Millions : 202

Growth (%) : 11

blank

03

Brand Name : NovoRapid

Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : NovoRapid

Denmark
arrow
CPHI Middle east
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 2,753

2019 Revenue in Millions : 2,937

Growth (%) : -6

blank

04

Brand Name : Ryzodeg

Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : Ryzodeg

Denmark
arrow
CPHI Middle east
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 210

2019 Revenue in Millions : 162

Growth (%) : 30

blank

05

Brand Name : Ryzodeg

IInsulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : Ryzodeg

Denmark
arrow
CPHI Middle east
Not Confirmed

IInsulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 261

2020 Revenue in Millions : 207

Growth (%) : 33

blank

06

Brand Name : NovoMix

Biphasic Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : NovoMix

Denmark
arrow
CPHI Middle east
Not Confirmed

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,447

2020 Revenue in Millions : 1,541

Growth (%) : -1

blank

07

Brand Name : Fiasp

Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : Fiasp

Denmark
arrow
CPHI Middle east
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 266

2020 Revenue in Millions : 222

Growth (%) : 26

blank

08

Brand Name : NovoRapid

Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : NovoRapid

Denmark
arrow
CPHI Middle east
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 2,429

2020 Revenue in Millions : 2,708

Growth (%) : -6

blank

09

Brand Name : NovoMix

Biphasic Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : NovoMix

Denmark
arrow
CPHI Middle east
Not Confirmed

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 1,119

2021 Revenue in Millions : 1,447

Growth (%) : -23

blank

10

Brand Name : Fiasp

Insulin Aspart

arrow
CPHI Middle east
Not Confirmed

Brand Name : Fiasp

Denmark
arrow
CPHI Middle east
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 292

2021 Revenue in Millions : 266

Growth (%) : 10

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty